Compare GRC & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRC | NBTX |
|---|---|---|
| Founded | 1933 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2020 |
| Metric | GRC | NBTX |
|---|---|---|
| Price | $49.55 | $22.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 91.0K | 50.1K |
| Earning Date | 10-24-2025 | 09-30-2025 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | ★ 31.51 | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $678,522,000.00 | $11,930,711.00 |
| Revenue This Year | $4.94 | N/A |
| Revenue Next Year | $4.02 | $136.64 |
| P/E Ratio | $25.93 | ★ N/A |
| Revenue Growth | ★ 3.19 | N/A |
| 52 Week Low | $30.87 | $2.82 |
| 52 Week High | $49.90 | $30.35 |
| Indicator | GRC | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 73.09 | 57.57 |
| Support Level | $45.80 | $20.83 |
| Resistance Level | $46.94 | $23.77 |
| Average True Range (ATR) | 1.15 | 0.88 |
| MACD | 0.45 | 0.17 |
| Stochastic Oscillator | 96.46 | 77.16 |
Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.